Dr. Brad McGregor

And then we look forward to the follow-up studies, right?

So we have a similar trial versus cisplatin, which is completely accrual.

We look forward to seeing those results.

But I think it's exciting.

And again, I think it's an offer opportunity to cure more patients with a defined course of therapy.

I mean, I think as the therapy in the paraplegic space has changed,

This is like probably the most important trial that will not directly impact patient care for live patients.

Just because we're not going to be having patients.

I mean, I think to me, it makes me really start thinking about like, what do we mean by adjuvant therapy, right?

So if you have a positive ctDNA, that's not really adjuvant.

That's like early metastatic treatment, right?

Because now you have evidence and metastatic.

disease.

It's like a near guarantee that they're going to relapse if you look at them raw.

Thank you.

I like that.

As opposed to, like, what does add really mean?

And so I think N3-001 is critical, right?

It shows us that early intervention on a positive CDA test improves outcomes.

And so that is what that says.